about
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.Real-world data on nivolumab treatment of non-small cell lung cancer.GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data.The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathwaysHigh number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival.Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids.Years of life lost as a measure of cancer burden on a national levelExpression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancerUnique microRNA-profiles in EGFR-mutated lung adenocarcinomas.Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking.Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer.Stereotactic body radiation therapy is effective and safe in patients with early-stage non-small cell lung cancer with low performance status and severe comorbidityOsteopontin is a prognostic biomarker in non-small cell lung cancer.The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypesNUT expression in primary lung tumoursTP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients.Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancerClinical significance of disseminated tumour cells in non-small cell lung cancerA unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer.Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease.Integrative genome analyses identify key somatic driver mutations of small-cell lung cancerHypoxia as a cause of treatment failure in non-small cell carcinoma of the lung.Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer.Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer.The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.Implementation of lung cancer CT screening in the Nordic countries.Rituximab efficiently depletes B cells in lung tumors and normal lung tissue.Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage.EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust.Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer.Ca2+/calmodulin-dependent protein kinase II is required for microcystin-induced apoptosis.Membrane-permeant, bioactivatable analogues of cGMP as inducers of cell death in IPC-81 leukemia cells.Ultrarapid caspase-3 dependent apoptosis induction by serine/threonine phosphatase inhibitors.Apoptosis induced by microinjection of cytochrome c is caspase-dependent and is inhibited by Bcl-2.NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors.Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.Sensitive and rapid detection of beta-galactosidase expression in intact cells by microinjection of fluorescent substrate.Human papilloma virus detection and typing in 334 lung cancer patients.
P50
Q27851615-8BA89FDE-40F6-4CB9-8251-57BC1310D677Q27851720-F91F0EFC-0AF1-45E1-AF21-9E0AB0240555Q31145059-853B29B7-22FC-4807-9BE1-66BCF7D73EF8Q31156446-23CC205C-9516-4053-973D-FF67087ECBFCQ33540190-8C971964-DE48-4CB5-AFAE-A08B3B1EA08EQ33742810-46E33E89-DF9F-42CE-BBF4-8D781BCF6017Q34045543-062FD8A1-A53B-417C-A4BD-DF9B333F88FAQ34113539-C04E8802-4AAA-428A-A204-37AD31F9F4DAQ34361505-2857A566-FA85-4073-BAF4-A20DE311C485Q34531091-1D92537F-3197-4D45-856D-E284852B5311Q34545220-913A1A7D-43CE-43D7-AE80-CD1C2D09A018Q34720505-74866DE9-9E44-45F1-87B4-BDDCED8C46D4Q34859171-5629C5E5-DAB4-4978-A899-E8AE40239681Q35038432-83EAD5B4-29E9-4F3E-996C-33B85D1A22DDQ35917825-D2E08323-E127-4546-9D01-D0A5CCF858B5Q36030365-23BB59B5-E4C8-4D91-8522-3145ABB00F40Q36889861-9634F593-FA24-4B23-AAB7-30F87AACF67BQ37018090-889BBC82-1229-431A-9B64-AC03CF1523CEQ37185823-66579ADA-5783-4E62-BFA8-1D7F95310119Q37392954-239221CF-824E-4626-8C23-7BB6FE8879C2Q37463885-A0571814-80C6-46D0-9DF8-F259BB09B408Q38322114-7B5E4BEC-9DA3-445B-A973-FE2682C74B09Q38378123-88AD8F4E-F1EB-414F-BFC6-04AEE59D3F28Q38636708-1AA78DB1-7344-4104-AC4B-2C9B40A1EAD9Q38781539-E80FBF63-3415-40D7-A70F-E77F749CAC3CQ38978231-9F65B3C6-D0ED-432C-8877-308F55992A24Q39344447-EC44F3D7-42FF-46D8-9926-8742EA06FE03Q39680704-BFC6A01C-3797-46E6-816A-FB07368F6382Q40483664-B32B0796-6526-4A9F-820C-39F3E1B39CD5Q40600788-D3B19C0F-0EC9-4221-BD21-CA50072C055AQ40612067-8B161F01-8BD8-446A-9757-9CB3E2DD78E8Q40768035-395C6BE4-3262-4F75-A234-ECBBA0A5BD71Q40890476-175E99F1-2727-4D80-B0F8-FCA235BDF607Q40915045-D3A3E441-BE5A-4FE9-86C1-347ED9267F50Q40961124-589FB589-C92C-4A8E-AD2A-C1688C09837DQ41010553-95FE514D-C221-4804-8D3E-E8CF641413C0Q41101024-7173640A-4E48-4E4E-B04C-D46331FA7689Q41192457-7048A32F-1561-48CB-8598-0CF1374EE4E4Q41317378-A1E2B87A-FE3E-4B3B-A596-CDC9E374C7EBQ42242155-AD0AE832-63AD-4BD4-A618-68055A26EA39
P50
description
Noors oncoloog
@nl
Norwegian researcher
@en
norsk onkolog
@nb
taighdeoir Ioruach
@ga
name
Odd Terje Brustugun
@ast
Odd Terje Brustugun
@da
Odd Terje Brustugun
@de
Odd Terje Brustugun
@en
Odd Terje Brustugun
@es
Odd Terje Brustugun
@fr
Odd Terje Brustugun
@ga
Odd Terje Brustugun
@nb
Odd Terje Brustugun
@nl
Odd Terje Brustugun
@nn
type
label
Odd Terje Brustugun
@ast
Odd Terje Brustugun
@da
Odd Terje Brustugun
@de
Odd Terje Brustugun
@en
Odd Terje Brustugun
@es
Odd Terje Brustugun
@fr
Odd Terje Brustugun
@ga
Odd Terje Brustugun
@nb
Odd Terje Brustugun
@nl
Odd Terje Brustugun
@nn
altLabel
Odd Brustugun
@nb
Odd T Brustugun
@en
Odd T. Brustugun
@nb
prefLabel
Odd Terje Brustugun
@ast
Odd Terje Brustugun
@da
Odd Terje Brustugun
@de
Odd Terje Brustugun
@en
Odd Terje Brustugun
@es
Odd Terje Brustugun
@fr
Odd Terje Brustugun
@ga
Odd Terje Brustugun
@nb
Odd Terje Brustugun
@nl
Odd Terje Brustugun
@nn
P106
P21
P214
3368149108452568780004
P2287
P27
P31
P496
0000-0002-5153-8391
P5008
P7859
viaf-3368149108452568780004